Despite the introduction of angiotensin-converting
|
|
- Brian Hodge
- 6 years ago
- Views:
Transcription
1 doi:./j x O RIGINAL A RTICLE Sudden Cardiac Arrest in Patients With Severe Nonischemic Heart Failure: Risk Stratification With the Heart Failure Survival Sce Despite the introduction of angiotensin-converting enzyme inhibits, b-blockers, and spironolactone, a substantial number of congestive heart failure (CHF) patients die, many of them suddenly, even after clinical improvement. 1 A shift to sudden death rather than death from pump failure is observed under optimized medical therapy. Sudden cardiac arrests (SCAs) account f me than half of fatal events in stabilized heart transplant candidates. Thus, the control of sudden death in this population becomes increasingly imptant. Although it has been shown to be effective in patients with less advanced disease (New Yk Heart Association [NYHA] stages II III), prophylactic implantation of implantable cardioverter-defibrillats (ICDs) is restricted to select patients due to economic limitations in many countries. Therefe, patients who are most in need of a device have to be identified. Furtherme, in patients with nonischemic cardiomyopathy, there is controversy over the predominant mode of death and whether an ICD would be beneficial in these patients., Risk stratification f SCA is traditionally based on results from many single measures including (but not exclusively) conary angiography, exercise testing, NYHA functional class, left ventricular ejection fraction (LVEF), arrhythmias in longterm ambulaty recdings, signal-averaged electrocardiography, QT-interval duration, dispersion, T-wave alternans, heart rate variability, bareflex sensitivity, programmed electrical stimulation, and brain-natriuretic peptide levels. However, no single parameter is generally useful in identifying patients at very high risk f sudden cardiac death. Furtherme, there are me data available The auths wanted to investigate whether the heart failure survival sce (HFSS) is useful f sudden cardiac arrest (SCA) risk stratification and whether there is a difference with regard to congestive heart failure (CHF) etiology. Data of 1 severe CHF patients (New Yk Heart Association III IV % %, mean age years, mean left ventricular ejection fraction %%) during the period from 1 00 were analyzed. The HFSS was calculated using the Aaronson fmula. SCA-free survival was calculated using Kaplan Meier analysis accding to the etiology of CHF: conary artery disease (CAD) (n=1) vs no CAD (n=). In regard to SCA risk the auths found no significant overall difference between patients with without CAD. Non-CAD HFSS high-risk patients had a significantly higher risk f SCA than all the other groups (P<.001). The HFSS is useful f the detection of a subgroup of non-cad severe CHF patients at a very high risk f SCA. Congest Heart Fail. 00. Ó00 Le Jacq Maria A. Castel, MD; 1 Herbert Nägele, MD From the Thax Institute, Hospital Clinic, Villarroel, Barcelona, Spain; 1 and St Adolfstift, Medical Clinic, Reinbek, Hamburg, Germany Address f crespondence: Maria A. Castel, MD, Thax Institute, Hospital Clinic, Villarroel 10, 00 Barcelona, Spain acastel@gmx.de Manuscript received April, 00; revised October 1, 00; accepted November, 00 f patients with conary artery disease (CAD) than f non-cad patients. The heart failure survival sce (HFSS), by using a combination of common clinical variables, provides a me robust risk stratification tool f total mtality in the general population of heart failure patients compared with other measures such as isolated peak oxygen consumption (VO ). It gives a robust measure of prognosis and stratification f heart transplant in patients with and without b-blockers and in men and women. 1 A European study showed that this measure is very useful f the detection of patients who might profit from heart transplant. Therefe, in this present study we investigate whether the HFSS is useful f risk stratification of SCA events in a population of heart transplant candidates with regard to different CHF etiologies. C H F 0 B Methods We analyzed data from 1 severe CHF patients (NYHA III IV % %, mean age years, mean LVEF %%) submitted f evaluation of heart transplant during the period The mean observation time was..0 years. The clinical characteristics of the patient population are listed in the Table. The presence of CAD was defined as the occurrence of at least 0% stenosis of at least one maj conary artery. The assessments included physical examination, serum chemistries, and the parameters of the HFSS. Peak VO was determined during maximal treadmill exercise using a modified Naughton protocol and a metabolic cart (Metalyzer II; Ctex, Dresden, Germany). If a patient could not exercise, the resting VO value (Fick method) of the baseline right heart 1 November December 00 1 Dispatch:.1.0 Journal: CHF CE: Balaji Prasad Journal Name Manuscript No. Auth Received: No. of pages: PE: Venkatesh
2 Table. Patients Characteristics Stratified by Etiology and Heart Failure Survival Sce CAD NON-CAD HIGH RISK (.1) MEDIUM RISK (.0.0) LOW RISK (.) HIGH RISK (.1) MEDIUM RISK (.0.0) LOW RISK (.) No. 1 Men, % Mean age, y....1 Body mass index, kg m ( ) ( ) ( ) ( ) ( ) ( ) Peak oxygen consumption, ( ) ( ) (1 0) ( ) ( 1) (1 1) ml kg min a Ejection fraction, % a 1 ( 0) (0 0) (0 ) 0 (1 0) (1 ) ( ) Heart rate, beats min a 0 ( ) (0 ) ( 0) 1 (0 ) 0 ( ) ( ) Mean blood pressure, mm Hg a 0 ( ) (0 ). ( ) 0 ( ) 0 ( ) 0 (0 1) Sodium, meq L a 1 ( 1) 1 (1 1) 1 (1 1) (1 1) 1 (1 1) 1 (1 1) QRS, ms a 1 (0 1) 1 (0 ) 0 (0 1) 1 (0 10) 1 (0 1) (0 1) Abbreviation: CAD, conary artery disease. Nonparametric data are presented as medians (intraquartile range). a Same etiology P<.001 between risk groups. catheterization was used (in 1% of cases). The LVEF was determined using echocardiography. The mean arterial blood pressure was obtained invasively by cannulation of radial arteries during routine right heart catheterization f the determination of pulmonary and peripheral vascular resistance. These procedures were perfmed after intake of chronic heart failure medication. The HFSS was derived f each patient from clinical parameters: the presence of CAD, heart rate, LVEF, mean arterial blood pressure, QRS duration > ms, peak VO, and serum sodium concentration. Dichotomous variables were coded as 1 (present) 0 (absent). Each value f the continuous and dichotomous variables was multiplied by a model coefficient, derived from a proptional hazards model. The products were summed, and the absolute value was taken as the HFSS accding to the following equation: 1 ((0.CAD)+(0.0heart rate)+ ()0.0LVEF)+()0.0mean arterial pressure)+(0.qrs >)+ ()0.0peakVO )+()0.0sodium). F the HFSS, risk strata were defined as low-risk HFSS.1, medium-risk HFSS..0, high-risk HFSS <. using previously described cutoffs. SCA-free survival was calculated with Kaplan Meier analysis accding to the underlying etiology of CHF (ischemic [n=1] vs nonischemic [n=]). Patients with defibrillats already implanted and a class I indication f an ICD at that time (eg, previous documented tachyarrhythmic cardiac arrest) were excluded from the analysis. Also, patients who had to be immediately hospitalized after first evaluation f high-urgent heart transplant were excluded from analysis. The medical therapy of the patients was individually tailed. Only patients who were not improving were processed to heart transplant. A total of % of patients received a heart transplant in long-term follow-up. Heart transplant was a censing event. Patients were either followed prospectively in our outpatient clinic interviewed by regular phone calls; reasons f death events were noted and classified as sudden nonsudden. SCA 1 November December 00
3 was defined as death (witnessed unwitnessed) a successful resuscitation within 1 hour of symptoms and documentation of a ventricular tachyarrhythmia without premonity symptoms during a clinically stable period. Death after a period of deteriation with signs and symptoms of CHF despite maximal medical treatment was classified as resulting from progressive CHF. With regard to the underlying arrhythmia, additional infmation was sought through electrocardiography interrogation of pacemaker stage. In case of SCA at home, relatives were asked about the clinical status of the patient in the days befe the event. We used SCA plus sudden death as a combined end point rather than sudden death solely because both situations will, in most cases, result in a class I indication f ICD implantation. Statistical Analysis. Differences in the results of clinical and hemodynamic data were checked f significance by means of the Student t test f matched pairs and are expressed as mean SD. Nonparametric data were checked f significance with Wilcoxon tests and are expressed as medians with intraquartile ranges. Survival rate was calculated by Kaplan Meier analysis (heart transplant and death other than sudden death were censed), and differences between groups were tested f significance by multivariance analysis (with Bonferroni crection) and the log-rank test (Winstat.1, Kalmia Co, Inc, Cambridge, MA, and SPSS f Windows.1, SPSS Inc, Chicago, IL). TheriskofSCAwasexpressedasfreedom from such an event. Results Our patient population was representative f a coht of patients with severe heart failure (NYHA III IV) at study entry (Table). Risk stratification accding to the HFSS showed a typical separation in heart failure parameters. We found a total of 1 SCA events. Of these cases, 1 % were successfully resuscitated. In % of cases there was no infmation about the heart rhythm at COLOUR COLOUR time of death. SCA cases differed in general from non-sca cases by their lower HFSS sce (.0. vs.0.) (P<.01). No significant difference in SCA risk (expressed as freedom from such an event) was found over time between patients with without CAD (Figure 1). On further follow-up, groups of HFSS risk with CAD were separately analyzed and compared. No significant difference was shown in the risk f sudden death - SCA between these groups accding to our definition (Figure ). In contrast, patients with non-cad and a high-risk HFSS sce had a distinctive and significantly greater risk f SCA than the other non-cad groups (Figure ) (P<.001). We further analyzed possible relationshipsofbodymassindex(bmi)tothe HFSS and found a significantly lower BMI in the high-risk group (BMI low risk,. kg m ; BMI medium risk,. kg m ; BMI high risk,. kg m [P=.00 high-risk group vs others]). However, BMI did not separate between etiologies, when they were stratified accding the HFSS groups (Table). BMI showed consistently lower values in the high-risk groups. Patients with cardiac arrest (n=) did not differ from patients without this condition (n=) in terms of BMI (. vs.kg m ; P=not significant). Discussion In regard to patient characteristics accding to HFSS classes (Table), our coht was comparable to the heart transplant candidates studied by Deng and colleagues. Therefe, we think that our results can be extrapolated to other patients with severe heart failure, recommended f heart transplantation. Follow-up data revealed that our Figure 1. Freedom from sudden cardiac arrest (SCA) and disease etiology in conary artery disease (CAD) (n=1) vs non-cad (n=) patients. 0 indicates no CAD; 1, CAD. Figure. Freedom from sudden cardiac arrest (SCA) in conary artery disease (CAD) patients (n=1) stratified by heart failure survival sce (HFSS) P=not significant between the groups. 1 November December 00
4 COLOUR Figure. Freedom from sudden cardiac arrest (SCA) in non conary artery disease (CAD) patients (n=) stratified by heart failure survival sce (HFSS). * High-risk class vs others P<.001. REFERENCES 1 Bardy GH, Lee KL, Mark DB, et al. Amiodarone an implantable cardioverter-defibrillat f congestive heart failure. N Engl J Med. 00;:. patients with severe, but stabilized, CHF are at high risk f SCA irrespective of the underlying disease etiology, even after years (in fav of the non-cad patients) (Figure 1). Our data show no significant difference in SCA risk between HFSS groups within the coht of patients with CAD (Figure ). One pointisasomewhatlowerincidenceof SCA in the first observation years in the low-risk patients, but this advantage disappeared after years. Therefe, in this group, the HFSS adds little to our clinical distinction f sudden death risk stratification. CAD and non-cad CHF patients did not differ in their overall SCA risk and should therefe be treated similarly in regard to primary prevention measures (ICD). In our present studywehaveshownfthefirsttime, to our knowledge, that the HFSS is useful f the detection of a subgroup of non-cad severe CHF patients at very high risk f sudden cardiac death SCA (Figure ). In contrast, the BMI did not separate between CAD and non-cad patients, but the high-risk HFSS group in general showed lower BMI values, well fitting to the obesity paradox in CHF. The risk of SCA in this group appears to be substantially higher than observed by others. This may be due to the me advanced stage of disease in our coht. The risk seems to be dependent on data from first evaluation, irrespective of possible later improvement in NYHA classification, abolishing the need f heart transplant. In these patients f whom heart transplant has been deferred due to hemodynamic stabilization, an ICD is, in our opinion, an absolutely necessary safety net. The risk of sudden death is nonlinear over time (Figure and Figure ). The period of highest risk is the first year of observation. Therefe, a quick decision has to be made f early prophylactic ICD implantation. This concept should be evaluated in further studies. When taking into account that approximately 0% to 0% of SCA events are due to tachyarrhythmia, abenefitfrom early prophylactic ICD implantation can be expected. This recommendation is suppted by the results from the Defibrillats in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial. A causal relationship between a certain critical LVEF and the occurrence of SCA has yet not been demonstrated with respect to methods of risk stratification. That multiple mechanisms may contribute to the occurrence of ventricular tachycardia ventricular fibrillation impliesthatnosingletestislikelyto accurately predict risk of sudden death f all patients. Cardiac patients vary with both the presence and the type of underlying heart disease. In addition, Nägele H, Rödiger W. Sudden death and tailed medical therapy in elective candidates f heart transplantation. J Heart Lung Transplant. 1;1():. mechanisms underlying arrhythmias may depend on the stage of disease. Therefe, in our opinion, the decision f ICD implantation may be based on additional facts to LVEF and NYHA class. 1 Accdingly, in our patients, there was only a modest difference in LVEF between the high- and mediumrisk non-cad patients (Table). We suggest a sce covering different aspects of CHF, such as the HFSS, to aid decision-making at least in patients with non-cad and severe CHF. One could argue that high-risk HFSS patients should receive an ICD anyway accding to guidelines; however, several patients experienced their SCA events after a long follow-up in better NYHA classes and better LVEF (Figure ) and did not fulfill ICD implantation criteria any me. In this regard in our means data of first evaluation should be used irrespective of patient s individual improvement. It is unknown whether the recently published Seattle Heart Failure Model, 1 which incpates continuous and discrete variables to estimate 1-, -, and -year survival, is a better statistical tool to predict SCA. The HFSS is driven mainly by VO, which is not a part of the Seattle Heart Failure Model. In contrast, the Seattle Model is based on the diuretic dosage. Additional studies are needed to determine which model provides the best clinical guideline. Limitations Our study is a retrospective single center analysis and is therefe limited. A Cox proptional hazards model that includes as covariates HFSS groups was not perfmed because of colinearity of variables. Furtherme, our results were obtained befe the wide application of cardiac resynchronization therapy (which itself may alter the risk of sudden cardiac arrest). Therefe, our results should be confirmed in multicenter prospective investigations including modern device therapy. Buxton AE. Not everyone with an ejection fraction <0% should receive an implantable cardioverter-defibrillat. Circulation. 00; 1:. 1 November December 00
5 Bänsch D, Antz M, Bocz S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 00; : 1. Kadish A, Dyer A, Daubert JP, et al. Investigats prophylactic defibrillat implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 00;0: 1 1. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1;: 1. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with conary artery disease. N Engl J Med. 1;: Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillat in patients with conary disease at high risk f ventricular arrhythmia. Multicenter Automatic Defibrillat Implantation Trial Investigats. N Engl J Med. 1;: 1 1. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillat in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 00;:. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulaty patients referred f cardiac transplant evaluation. Circulation. 1;:. Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulaty patients with severe heart failure on beta-blocker therapy. Am J Cardiol. 00;:. 1 Green P, Lund LH, Mancini D. Comparison of peak exercise oxygen consumption and the Heart Failure Survival Sce f predicting prognosis in women versus men. Am J Cardiol. 00;:. Deng MC, De Meester JMJ, Smits JMA, et al. Effect of receiving a heart transplant: analysis of a national coht entered on to a waiting list, stratified by heart failure severity. BMJ. 000;1:. Mancini D, Katz S, Donchez L, et al. Coupling of hemodynamic measurements with oxygen consumption during exercise does not improve risk stratification in patients with heart failure. Circulation. 1;:. Hwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mtality in patients with heart failure. JAm Coll Cardiol. 001;:. Nägele H, Hashagen S, Azizi M, et al. Analysis of terminal arrhythmias sted in the memy of pacemakers from patients dying suddenly. Europace. 00;:0. 1 Levy W, Mozaffarian D, Linker D, et al. The Seattle Heart Failure model: the prediction of survival in heart failure. Circulation. 00; :1. 1 November December 00
6 Auth Query Fm Journal: CHF Article: 0 Dear Auth, During the copy-editing of your paper, the following queries arose. Please respond to these by marking up your proofs with the necessary changes/additions. Please write your answers on the query sheet if there is insufficient space on the page proofs. Please write clearly and follow the conventions shown on the attached crections sheet. If returning the proof by fax do not write too close to the paper s edge. Please remember that illegible mark-ups may delay publication. Many thanks f your assistance. Query reference Query Remarks Q1 AUTHOR: Please provide suggested sht title running footer.
7 MARKED PROOF Please crect and return this set Please use the proof crection marks shown below f all alterations and crections. If you wish to return your proof by fax you should ensure that all amendments are written clearly in dark ink and are made well within the page margins. Instruction to printer Leave unchanged Insert in text the matter indicated in the margin Delete Substitute character substitute part of one me wd(s) Change to italics Change to capitals Change to small capitals Change to bold type Change to bold italic Change to lower case Change italic to upright type Change bold to non-bold type Insert superi character Insert inferi character Insert full stop Insert comma Insert single quotation marks Textual mark under matter to remain through single character, rule underline through all characters to be deleted through letter through characters Encircle matter to be changed through character where required Marginal mark New matter followed by new character new characters under character e.g. over character e.g. and/ Insert double quotation marks and/ Insert hyphen Start new paragraph No new paragraph Transpose Close up linking characters Insert substitute space between characters wds through character where required Reduce space between characters wds between characters wds affected
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationPrimary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life
Chapter 3 Primary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life Guido H. van Welsenes, MS, Johannes B. van Rees, MD, Joep Thijssen, MD, Serge
More informationSelecting patients for heart transplantation: Comparison of the Heart Failure Survival Score (HFSS) and the Seattle Heart Failure Model (SHFM)
http://www.jhltonline.org Selecting patients for heart transplantation: Comparison of the Heart Failure Survival Score (HFSS) and the Seattle Heart Failure Model (SHFM) Ayumi Goda, MD, PhD, a,b Paula Williams,
More informationClosing the energy gap to prevent weight gain in China
obr_0 obesity reviews Closing the energy gap to prevent weight gain in China F. Zhai,H.Wang,Z.Wang, B. M. Popkin and C. Chen 0 National Institute of Nutrition and Food Safety, Chinese Center f Disease
More informationArrhythmias Focused Review. Who Needs An ICD?
Who Needs An ICD? Cesar Alberte, MD, Douglas P. Zipes, MD, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN Sudden cardiac arrest is one of the most common causes
More informationComparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure
HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart
More information20 ng/ml 200 ng/ml 1000 ng/ml chronic kidney disease CKD Brugada 5 Brugada Brugada 1
Symposium 39 45 1 1 2005 2008 108000 59000 55 1 3 0.045 1 1 90 95 5 10 60 30 Brugada 5 Brugada 80 15 Brugada 1 80 20 2 12 X 2 1 1 brain natriuretic peptide BNP 20 ng/ml 200 ng/ml 1000 ng/ml chronic kidney
More informationWhat Every Physician Should Know:
What Every Physician Should Know: The Canadian Heart Rhythm Society estimates that, in Canada, sudden cardiac death (SCD) is responsible for about 40,000 deaths annually; more than AIDS, breast cancer
More informationShocks burden and increased mortality in implantable cardioverter-defibrillator patients
Shocks burden and increased mortality in implantable cardioverter-defibrillator patients Gail K. Larsen, MD, MPH,* John Evans, MD, William E. Lambert, PhD,* Yiyi Chen, PhD,* Merritt H. Raitt, MD* From
More informationRisk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
More informationOriginal Article Fragmented QRS as a Predictor of Appropriate Implantable Cardioverter-defibrillator Therapy
4 Original Article Fragmented QRS as a Predictor of Appropriate Implantable Cardioverter-defibrillator Therapy Sirin Apiyasawat, Dujdao Sahasthas, Tachapong Ngarmukos, Pakorn Chandanamattha, Khanchit Likittanasombat
More informationPrimary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: signal_averaged_ecg 7/1992 10/2017 10/2018 10/2017 Description of Procedure or Service Signal-averaged electrocardiography
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary
More informationSurgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011
Surgery and device intervention for the elderly with heart failure: assessing the need Devices and Technology for heart failure in 2011 Assessing cardiovascular function / prognosis (in the elderly): composite
More informationT-Wave Alternans. Policy # Original Effective Date: 06/05/2002 Current Effective Date: 09/17/2014
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationMEDICAL POLICY POLICY TITLE T-WAVE ALTERNANS TESTING POLICY NUMBER MP
Original Issue Date (Created): August 23, 2002 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY T-wave alternans is considered investigational as a technique
More informationRita Calé, Miguel Mendes, António Ferreira, João Brito, Pedro Sousa, Pedro Carmo, Francisco Costa, Pedro Adragão, João Calqueiro, José Aniceto Silva.
Peak Circulatory Power : a new parameter of cardiopulmonary exercise testing to predict arrhythmic events in patients with implantable cardioverter defibrillator for primary prevention Rita Calé, Miguel
More informationWho does not need a primary preventive ICD?
Who does not need a primary preventive ICD? Hildegard Tanner, Bern Universitätsklinik für Kardiologie Disclosure of potential conflicts of interest Travel grants for educational purposes from: Biosense
More informationRe: National Coverage Analysis (NCA) for Implantable Cardioverter Defibrillators (CAG R4)
December 20, 2017 Ms. Tamara Syrek-Jensen Director, Coverage & Analysis Group Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: National Coverage Analysis (NCA) for
More informationCRT-P or CRT-D From North Alberta to Nairobi
CRT-P or CRT-D From North Alberta to Nairobi Dr Mzee Ngunga Aga Khan University Hospital Nairobi KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web:
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review
More informationMicrovolt T-Wave Alternans and the Risk of Death or Sustained Ventricular Arrhythmias in Patients With Left Ventricular Dysfunction
Journal of the American College of Cardiology Vol. 47, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.11.026
More informationChapter 3. Eur Heart J 2009; 30:
Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention ICD Recipients: Long-term Followup of the Leiden Out-of- Hospital Cardiac Arrest Study (LOHCAT) C. Jan Willem Borleffs, MD 1, Lieselot
More informationCardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the
More informationAtrial fibrillation (AF) is a disorder seen
This Just In... An Update on Arrhythmia What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia. Beth L. Abramson,
More informationPrevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias
Prevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias The Toronto ACS Summit Toronto, March 1, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology
More informationEvaluation of Sum Absolute QRST Integral as a Clinical Marker for Ventricular Arrhythmias. Markus Kowalsky Group 11
Evaluation of Sum Absolute QRST Integral as a Clinical Marker for Ventricular Arrhythmias Markus Kowalsky Group 11 Selected Paper Ventricular arrhythmia is predicted by sum absolute QRST integral but not
More informationQRS Duration Does Not Predict Occurrence of Ventricular Tachyarrhythmias in Patients With Implanted Cardioverter-Defibrillators
Journal of the American College of Cardiology Vol. 46, No. 2, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.03.060
More informationSCOMPENSO CARDIACO: IL PUNTO DELLA RICERCA
Journal Club 19 Marzo 2010 SCOMPENSO CARDIACO: IL PUNTO DELLA RICERCA Alessandro Giordano Prevalence of heart failure by sex and age (NHANES:1999-2004) Circulation 2007 Incidence of heart failure by age
More informationNHS. Implantable cardioverter defibrillators (ICDs) for arrhythmias. National Institute for Health and Clinical Excellence. Issue date: January 2006
NHS National Institute for Health and Clinical Excellence Issue date: January 2006 Implantable cardioverter defibrillators (ICDs) for arrhythmias Understanding NICE guidance information for people with
More informationIt has been shown from meta-analysis of randomized clinical trials that patients with a pre-crt QRS duration (QRSD) >150 ms benefit
Cardiac Resynchronization Therapy may be detrimental in patients with a Very Wide QRSD > 180 ms (VWQRSD) and Right Bundle Branch Block Morphology: Analysis From the Medicare ICD Registry Varun Sundaram
More informationRate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications.
Article ID: WMC004618 ISSN 2046-1690 Rate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications. Peer review status: No Corresponding
More information2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential
More informationHeart Failure and Implantable Cardioverter Defibrillator (ICD) Therapy: Update and Perspective on Current Primary Prevention Trials
Journal of Cardiac Failure Vol. 8 No. 3 2002 Perspectives Heart Failure and Implantable Cardioverter Defibrillator (ICD) Therapy: Update and Perspective on Current Primary Prevention Trials LESLIE A. SAXON,
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationThe ROBINS-I tool is reproduced from riskofbias.info with the permission of the authors. The tool should not be modified for use.
Table A. The Risk Of Bias In Non-romized Studies of Interventions (ROBINS-I) I) assessment tool The ROBINS-I tool is reproduced from riskofbias.info with the permission of the auths. The tool should not
More informationLong-Term Prognosis in Recipients of Implantable Cardioverter-Defibrillators for Secondary Preventions in Taiwan A Multicenter Registry Study
Mini Forum for EPS Acta Cardiol Sin 2014;30:22 28 Long-Term Prognosis in Recipients of Implantable Cardioverter-Defibrillators for Secondary Preventions in Taiwan A Multicenter Registry Study Tze-Fan Chao,
More informationMichel Mirowski and colleagues ABSTRACT CARDIOLOGY. ICD Update: New Evidence and Emerging Clinical Roles in Primary Prevention of Sudden Cardiac Death
ICD Update: New Evidence and Emerging Clinical Roles in Primary Prevention of Sudden Cardiac Death Ronald D. Berger, MD, PhD, FACC ABSTRACT PURPOSE: To review recent major randomized trials of implantable
More informationCardiac resynchronization therapy for mild-to-moderate heart failure
For reprint orders, please contact reprints@expert-reviews.com Cardiac resynchronization therapy for mild-to-moderate heart failure Expert Rev. Med. Devices 8(3), 313 317 (2011) Haran Burri Electrophysiology
More informationDevice Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx
Device Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx Charles Gottlieb, MD Director of Electrophysiology Abington Memorial Hospital Heart Failure Mortality Mechanism of death
More informationSeveral studies of the primary prevention. Original Research
Original Research Hellenic J Cardiol 2015; 56: 230-236 Inducibility of Ventricular Arrhythmia and Tachyarrhythmia Recurrences in Patients with Implantable Defibrillator Giuseppe Stabile 1, Paolo Gallo
More informationSynopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist
Synopsis of Management on Ventricular arrhythmias M. Soni MD Interventional Cardiologist No financial disclosure Premature Ventricular Contraction (PVC) Ventricular Bigeminy Ventricular Trigeminy Multifocal
More informationCurrent guidelines for device-based therapy of cardiac
Long-Term Benefit of Primary Prevention With an Implantable Cardioverter-Defibrillator An Extended 8-Year Follow-Up Study of the Multicenter Automatic Defibrillator Implantation Trial II Ilan Goldenberg,
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationJournal of the American College of Cardiology Vol. 41, No. 12, by the American College of Cardiology Foundation ISSN /03/$30.
Journal of the American College of Cardiology Vol. 41, No. 12, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00467-4
More informationCardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition
Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Table of Contents Volume 1 Chapter 1: Cardiovascular Anatomy and Physiology Basic Cardiac
More informationClinical Investigations
Clinical Investigations Comparison of the Seattle Heart Failure Model and Cardiopulmonary Exercise Capacity for Prediction of Death in Patients With Chronic Ischemic Heart Failure and Intracoronary Progenitor
More informationICD Therapy in Survivors of Sudden Cardiac Death Awaiting Heart Transplantation
CD Therapy in Survivors of Sudden Cardiac Death Awaiting Heart Transplantation Michael Grimm, MD, Georg Grimm, MD, PhD, Andreas Zuckermann, MD, Georg Wieselthaler, MD, Michael Feuerstein, MS, Homayoun
More informationBrian Olshansky, MD, FHRS,* John D. Day, MD, FHRS, Renee M. Sullivan, MD,* Patrick Yong, MSEE, Elizabeth Galle, MS, Jonathan S. Steinberg, MD, FHRS
Does cardiac resynchronization therapy provide unrecognized benefit in patients with prolonged PR intervals? The impact of restoring atrioventricular synchrony: An analysis from the COMPANION Trial Brian
More informationClinical Investigations
Clinical Investigations Natural History and Implantable Cardioverter-Defibrillator Implantation After Revascularization for Stable Coronary Artery Disease With Depressed Ejection Fraction Address for correspondence:
More informationThe Italian Implantable Cardioverter- Defibrillator Registry. A survey of the national activity during the years
The Italian Implantable Cardioverter- Defibrillator Registry. A survey of the national activity during the years 2001-2003 Alessandro Proclemer, Marco Ghidina*, Gloria Cicuttini*, Dario Gregori*, Paolo
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationRisk Stratification and Benefit of ICD-Therapy in Congestive Heart Failure Patients
120 April 2001 Risk Stratification and Benefit of ICD-Therapy in Congestive Heart Failure Patients P. SCHIRDEWAHN, G. HINDRICKS, H. KOTTKAMP Department of Cardiology, University of Leipzig Heart Center,
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationCongestive Heart Failure
Congestive Heart Failure Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology findings from the Heart Failure and A Controlled Trial Investigating Outcomes
More informationNoninvasive Predictors of Sudden Cardiac Death
2011 년순환기관련학회춘계통합학술대회 Noninvasive Predictors of Sudden Cardiac Death 영남대학교의과대학순환기내과학교실신동구 Diseases associated with SCD Previous SCD event Prior episode of ventricular tachyarrhythmia Previous myocardial
More informationSummary, conclusions and future perspectives
Summary, conclusions and future perspectives Summary The general introduction (Chapter 1) of this thesis describes aspects of sudden cardiac death (SCD), ventricular arrhythmias, substrates for ventricular
More informationChapter 2. Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients
Chapter 2 Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients Guido H. van Welsenes, MS, Johannes B. van Rees, MD, C. Jan Willem Borleffs, MD, PhD, Suzanne
More informationEditorial: Sudden Death in Heart Failure: An Ounce of Prediction is Worth a Pound of Prevention
Editorial: Sudden Death in Heart Failure: An Ounce of Prediction is Worth a Pound of Prevention Sudden Cardiac Death Ragavendra R. Baliga, MD, MBA Consulting Editors James B. Young, MD Sudden cardiac death
More informationCME Article Brugada pattern masking anterior myocardial infarction
Electrocardiography Series Singapore Med J 2011; 52(9) : 647 CME Article Brugada pattern masking anterior myocardial infarction Seow S C, Omar A R, Hong E C T Cardiology Department, National University
More information/$ -see front matter 2011 Heart Rhythm Society. All rights reserved. doi: /j.hrthm
Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial
More informationSignal-Averaged Electrocardiography (SAECG)
Medical Policy Manual Medicine, Policy No. 21 Signal-Averaged Electrocardiography (SAECG) Next Review: April 2018 Last Review: April 2017 Effective: May 1, 2017 IMPORTANT REMINDER Medical Policies are
More informationCognitive Control: Social Evolution and Emotional Regulation
0 0 0 0 Topics in Cognitive Science (0) Copyright Ó 0 Cognitive Science Society, Inc. All rights reserved. ISSN: - print / - online DOI: 0./j.-.0.0.x Abstract Cognitive Control: Social Evolution and Emotional
More informationEffectiveness of Implantable Cardioverter-Defibrillator Therapy for Heart Failure Patients according to Ischemic or Non-Ischemic Etiology in Korea
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Effectiveness of Implantable Cardioverter-Defibrillator Therapy for Heart Failure Patients according to Ischemic
More informationJournal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00608-7 The Prognostic
More informationthat number is extremely high. It s 16 episodes, or in other words, it s 14, one-four, ICD shocks per patient per day.
Doctor Karlsner, Doctor Schumosky, ladies and gentlemen. It s my real pleasure to participate in this session on controversial issues in the management of ventricular tachycardia and I m sure that will
More informationStudy population The study population comprised patients with NIDCM and asymptomatic NSVT. The inclusion criteria were:
Amiodarone versus implantable cardioverter-defibrillator: randomized nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT Strickberger S A, Hummel J D, Bartlett
More informationHeart Failure Overview. Dr Chris K Y Wong
Heart Failure Overview Dr Chris K Y Wong Heart Failure: A Growing, Global Health Issue Heart Failure 23 Million Afflicted Global Impact Worldwide ~23 million peopleworldwide afflicted with CHF 1 Exceeds
More informationMEDICAL POLICY SUBJECT: MICROVOLT T-WAVE ALTERNANS
MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationPublic Statement: Medical Policy Statement:
Medical Policy Title: Cardioverter- ARBenefits Approval: 09/7/2011 Defibrillators Effective Date: 01/01/2012 Document: ARB0096 Revision Date: Code(s): C1721, C1722, C1777, C1882, C1895, C1896 and C1899
More informationG Lin, R F Rea, S C Hammill, D L Hayes, P A Brady
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA Correspondence to: Dr Peter A Brady, MD, FRCP, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA; brady.peter@mayo.edu Accepted
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationResponse of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT
Response of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT Heart Rhythm Society (May 11, 2012) Colin L. Doyle, BA,*
More informationAssessment of Defibrillation Threshold upon Implantable Cardioverter-Defibrillator implant in Relation to patient s prognosis
Assessment of Defibrillation Threshold upon Implantable Cardioverter-Defibrillator implant in Relation to patient s prognosis Investigator: Keiko Saito, MD Mentor: Yuji Saito, MD, PhD, FACP, FACC Department
More informationJournal of the American College of Cardiology Vol. 44, No. 7, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 44, No. 7, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.06.063
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationEffects of Statin Therapy on Arrhythmic Events and Survival in Patients With Nonischemic Dilated Cardiomyopathy
Journal of the American College of Cardiology Vol. 48, No. 6, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.05.053
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationBiomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D.
Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D. Professor of Medicine Division of Cardiology University of California, San Diego Disclosures Honoraria, Research Grants, Medtronic Honoraria,
More informationMeta-analysis of the implantable cardioverter defibrillator secondary prevention trials
European Heart Journal (2000) 21, 2071 2078 doi.10.1053/euhj.2000.2476, available online at http://www.idealibrary.com on Meta-analysis of the implantable cardioverter defibrillator secondary prevention
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationjournal of medicine The new england Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both
The new england journal of medicine established in 1812 june 23, 2005 vol. 352 no. 25 Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both Scott
More informationSudden Cardiac Death Prevention: ICD Indications
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/sudden-cardiac-death-prevention-icdindications/3681/
More informationFOR TEACHERS ONLY. The University of the State of New York REGENTS HIGH SCHOOL EXAMINATION GEOMETRY
FOR TEACHERS ONLY The University of the State of New Yk REGENTS HIGH SCHOOL EXAMINATION GEOMETRY Wednesday, January 29, 2014 9:15 a.m. to 12:15 p.m., only SCORING KEY AND RATING GUIDE Mechanics of Rating
More informationWhere Does the Wearable Cardioverter Defibrillator (WCD) Fit In?
Where Does the Wearable Cardioverter Defibrillator (WCD) Fit In? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor of Medicine Director,
More informationHeart failure and sudden death
Heart failure and sudden death What did we learn so far from important ICD- and CRT trials? Helmut U. Klein M.D. University of Rochester Medical Center Heart Research Follow up Program Arrhythmic substrate
More informationThe concept of the implantable cardioverter-defibrillator (ICD) was introduced
Review Rohit Kedia, MD Mohammad Saeed, MD, FACC Implantable Cardioverter-Defibrillators Indications and Unresolved Issues Since the implantable cardioverter-defibrillator was first used clinically in 1980,
More informationThe Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia
The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia By Sandeep Joshi, MD and Jonathan S. Steinberg, MD Arrhythmia Service, Division of Cardiology
More informationHow to Assess Dyssynchrony
How to Assess Dyssynchrony Otto A. Smiseth, Professor, MD, PhD Oslo University Hospital None Conflicts of interest Cardiac resynchronization therapy effect on mortality Cleland JG et al, N Engl J Med
More informationESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309
ESC Guidelines Update 2008 ESC Guidelines Heart failure update 2008 For internal training purpose. 0 Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Effectiveness of Implantable Cardioverter-Defibrillators in Patients With Ischemic Heart Disease and Left Ventricular Dysfunction Paul S. Chan, MD, MSc; Theodore Chow, MD; Dean Kereiakes,
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationImaging in dilated cardiomyopathy : factors associated with a poor outcome
Imaging in dilated cardiomyopathy : factors associated with a poor outcome Johan De Sutter, MD, PhD, FESC AZ Maria Middelares Gent and University Gent - Belgium Dilated cardiomyopathy Cardiomyopathy with
More informationLong-term Preservation of Left Ventricular Function and Heart Failure Incidence with Ablate and Pace Therapy Utilizing Biventricular Pacing
The Journal of Innovations in Cardiac Rhythm Management, 3 (2012), 976 981 HEART FAILURE RESEARCH ARTICLE Long-term Preservation of Left Ventricular Function and Heart Failure Incidence with Ablate and
More information